주식/증권 ➡️ 중립 TG Therapeutics targets $890M-$905M 2026 U.S. BRIUMVI net revenue while anticipating subcutaneous Phase III results around year-end Seeking Alpha - Market News 08/03/2026 03:51:08 PM 3회 원문 기사 보기